Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision & Ophthalmology (ARVO) Annual Me...
April 28 2021 - 6:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, ocular surface diseases and
retinal diseases, today announced it will participate and have
poster presentations at the virtual Association for Research and
Vision in Ophthalmology (ARVO) Annual Meeting, to be held May 1-7,
2021. The posters will highlight topics ranging from additional
research findings on netarsudil to potential new product candidates
such as the new class of corticosteroid anti-inflammatories.
The following posters are independent research and not sponsored
by Aerie Pharmaceuticals:
- Title: Effect of the rho-kinase inhibitor Netarsudil on
established corneal neovascularization in a PAX-6 knockout mouse
model
- Date: Sunday, May 2, 2021
- Time: 9:00 – 10:45 a.m. Eastern Time
- Presenter: Timothy Janetos, M.D., Northwestern University
Feinberg School of Medicine
- Title: Adjunctive Use of Netarsudil in Refractory Glaucoma: 1
year Retrospective Analysis
- Date: Monday, May 3, 2021
- Time: 11:15 a.m. – 1:00 p.m. Eastern Time
- Presenter: Vladislav Bekerman, M.D., Rutgers University Medical
School Department of Ophthalmology & Visual Science
- Title: Efficacy of Netarsudil in Veterans with Severe Glaucoma
on Maximally Tolerated Medical Therapy
- Date: Monday, May 3, 2021
- Time: 11:15 a.m. – 1:00 p.m. Eastern Time
- Presenter: Reza Kianian, University of California Los Angeles
David Geffen School of Medicine
- Title: Pragmatic usage of Netarsudil: A Retrospective Chart
Review from a Tertiary Care Center
- Date: Tuesday, May 4, 2021
- Time: 10:15 a.m. – 12:00 noon Eastern Time
- Presenter: Nate Goergen, Ph.D., University of Nebraska Medical
Center
- Title: Effect of Rho-kinase Inhibition on a Patient-Derived
Model of Proliferative Vitreoretinopathy
- Date: Wednesday, May 5, 2021
- Time: 9:00 – 10:45 a.m. Eastern Time
- Presenter: Leslie Ramos, Schepens Eye Research Institute of
Massachusetts Eye and Ear
- Title: Efficacy of Netarsudil as an Additional Therapy for
Glaucoma in Patients Already on Maximally Tolerated Medical Therapy
- Date: Wednesday, May 5, 2021
- Time: 2:45 – 4:30 p.m. Eastern Time
- Presenter: Natacha Villega, M.D., Stanford University
The following posters are sponsored by Aerie
Pharmaceuticals:
- Title: Novel Corticosteroid Class Reduces Inflammation and
Lowers IOP in Animal Models
- Date: Wednesday, May 5, 2021
- Time: 2:45 – 4:30 p.m. Eastern Time
- First author: Kevin Carbajal, Ph.D., Aerie Pharmaceuticals
- Title: Ocular Pharmacokinetics of a Novel Class of
Corticosteroids with ROCK Inhibitory Activity and Potential for
Reduced Steroid-Associated Risks
- Date: Wednesday, May 5, 2021
- Time: 2:45 – 4:30 p.m. Eastern Time
- First author: Maria Zaretskaia, M.D., Aerie
Pharmaceuticals
- Title: The Synthesis and Testing of Rho Kinase Inhibitors
Reversibly Coupled to Corticosteroids for the Treatment of Ocular
Inflammatory Diseases
- Date: Friday, May 7, 2021
- Time: 2:15 – 4:00 p.m. Eastern Time
- First author: Mitchell deLong, Ph.D., Aerie
Pharmaceuticals
In addition, Casey Kopczynski, Ph.D., Aerie’s Chief Scientific
Officer, will participate in a Mini-Symposium entitled “Rho Kinase
Inhibitors, a New Class of Treatment for Glaucoma and Corneal
Disease” that will take place on Wednesday, May 5, 2021 from 5:00 –
6:45 p.m. Eastern Time. His podium presentation entitled “Clinical
experience with netarsudil, a new class of glaucoma drug targeting
trabecular outflow” will be from 5:07 – 5:20 p.m. Eastern Time.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma,
ocular surface diseases and retinal diseases. Aerie’s first
product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a
once-daily eye drop approved by the U.S. Food and Drug
Administration (FDA) for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, was launched in the United States in April 2018. In
clinical trials of Rhopressa®, the most common adverse reactions
were conjunctival hyperemia, corneal verticillata, instillation
site pain, and conjunctival hemorrhage. More information about
Rhopressa®, including the product label, is available at
www.rhopressa.com. Aerie’s second product for the reduction of
elevated IOP in patients with open-angle glaucoma or ocular
hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic
solution) 0.02%/0.005%, the first and only fixed-dose combination
of Rhopressa® and the widely-prescribed PGA (prostaglandin analog)
latanoprost, was launched in the United States in May 2019. In
clinical trials of Rocklatan®, the most common adverse reactions
were conjunctival hyperemia, corneal verticillata, instillation
site pain, and conjunctival hemorrhage. More information about
Rocklatan®, including the product label, is available at
www.rocklatan.com. Aerie continues to focus on global expansion and
the development of additional product candidates and technologies
in ophthalmology, including for wet age-related macular
degeneration and diabetic macular edema. More information is
available at www.aeriepharma.com.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements in this release include statements
regarding our intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the
duration and severity of the coronavirus disease (COVID-19)
outbreak, including the impact on our clinical and commercial
operations, demand for our products and financial results and
condition of our global supply chains; our expectations regarding
the commercialization and manufacturing of Rhopressa®, Rocklatan®,
Rhokiinsa® and Roclanda® or any product candidates, or other future
product candidates, including the timing, cost or other aspects of
their commercial launch; our commercialization, marketing,
manufacturing and supply management capabilities and strategies in
and outside of the United States; the success, timing and cost of
our ongoing and anticipated preclinical studies and clinical trials
for Rhopressa® and Rocklatan®, with respect to regulatory approval
outside of the United States, and any product candidates, or future
product candidates, including statements regarding the timing of
initiation and completion of the studies and trials; our
expectations regarding the effectiveness of Rhopressa®, Rocklatan®,
Rhokiinsa®, Roclanda® or any product candidates, or other future
product candidates; the timing of and our ability to request,
obtain and maintain FDA or other regulatory authority approval of,
or other action with respect to, as applicable, Rhopressa®,
Rocklatan® or any product candidates, preclinical implants or
future product candidates; the potential advantages of Rhopressa®
and Rocklatan® or any product candidates or future product
candidates; our plans to pursue development of additional product
candidates and technologies; our plans to explore possible uses of
our existing proprietary compounds beyond glaucoma, including
development of our retina program; our ability to protect our
proprietary technology and enforce our intellectual property rights
or to develop new intellectual property; and our expectations
regarding strategic operations, including our ability to in-license
or acquire additional ophthalmic products, product candidates or
technologies. In particular, FDA and European Medicines Agency
(EMA) approval of Rhopressa® and Rocklatan® do not constitute
regulatory approval of Rhopressa® and Rocklatan® in other
jurisdictions, and there can be no assurance that we will receive
regulatory approval for Rhopressa® and Rocklatan® in such other
jurisdictions, including Japan’s PMDA. In addition, FDA approval of
Rhopressa® and Rocklatan® do not constitute FDA approval of our
product candidates, or any future product candidates, and there can
be no assurance that we will receive FDA approval for our product
candidates or any future product candidates. By their nature,
forward-looking statements involve risks and uncertainties because
they relate to events, competitive dynamics, industry change and
other factors beyond our control, and depend on regulatory
approvals and economic and other environmental circumstances that
may or may not occur in the future or may occur on longer or
shorter timelines than anticipated. We discuss many of these risks
in greater detail under the heading “Risk Factors” in the quarterly
and annual reports that we file with the Securities and Exchange
Commission (SEC). Forward-looking statements are not guarantees of
future performance and our actual results of operations, financial
condition and liquidity, and the development of the industry in
which we operate may differ materially from the forward-looking
statements contained in this press release. Any forward-looking
statements that we make in this press release speak only as of the
date of this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210428005157/en/
Media: Tad
Heitmann 949-526-8747; theitmann@aeriepharma.com
Investors: Ami
Bavishi 908-947-3949; abavishi@aeriepharma.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Sep 2023 to Sep 2024